nodes	percent_of_prediction	percent_of_DWPC	metapath
Fondaparinux sodium—F10—Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus—F2—liver cancer	0.0179	0.0651	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Common Pathway—F2—liver cancer	0.0165	0.0602	CbGpPWpGaD
Fondaparinux sodium—F10—Removal of aminoterminal propeptides from gamma-carboxylated proteins—F2—liver cancer	0.0163	0.0593	CbGpPWpGaD
Fondaparinux sodium—F10—Gamma-carboxylation of protein precursors—F2—liver cancer	0.0163	0.0593	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Intrinsic Pathway—F2—liver cancer	0.0141	0.0513	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Complement and Coagulation Cascades—SERPINA1—liver cancer	0.014	0.051	CbGpPWpGaD
Fondaparinux sodium—F10—Gamma-carboxylation, transport, and amino-terminal cleavage of proteins—F2—liver cancer	0.0139	0.0505	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Formation of Fibrin Clot (Clotting Cascade)—F2—liver cancer	0.0095	0.0346	CbGpPWpGaD
Fondaparinux sodium—F10—Common Pathway—F2—liver cancer	0.00935	0.034	CbGpPWpGaD
Fondaparinux sodium—F10—Intrinsic Pathway—F2—liver cancer	0.00796	0.029	CbGpPWpGaD
Fondaparinux sodium—F10—Blood Clotting Cascade—F2—liver cancer	0.00796	0.029	CbGpPWpGaD
Fondaparinux sodium—F10—Complement and Coagulation Cascades—SERPINA1—liver cancer	0.00791	0.0288	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Glypican 1 network—VEGFA—liver cancer	0.00705	0.0257	CbGpPWpGaD
Fondaparinux sodium—F10—Post-translational protein modification—ADAMTS17—liver cancer	0.00675	0.0246	CbGpPWpGaD
Fondaparinux sodium—F10—Blood Clotting Cascade—SERPINE1—liver cancer	0.00662	0.0241	CbGpPWpGaD
Fondaparinux sodium—F10—PTM: gamma carboxylation, hypusine formation and arylsulfatase activation—F2—liver cancer	0.00656	0.0239	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Glypican 1 network—TGFB1—liver cancer	0.00648	0.0236	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Complement and Coagulation Cascades—F2—liver cancer	0.0064	0.0233	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Hemostasis—HBE1—liver cancer	0.00613	0.0223	CbGpPWpGaD
Fondaparinux sodium—F10—Formation of Fibrin Clot (Clotting Cascade)—F2—liver cancer	0.00537	0.0196	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Complement and Coagulation Cascades—SERPINE1—liver cancer	0.00532	0.0194	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Hemostasis—ANXA2—liver cancer	0.00379	0.0138	CbGpPWpGaD
Fondaparinux sodium—F10—Complement and Coagulation Cascades—F2—liver cancer	0.00362	0.0132	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—HBE1—liver cancer	0.00346	0.0126	CbGpPWpGaD
Fondaparinux sodium—Haemoptysis—Doxorubicin—liver cancer	0.00323	0.00445	CcSEcCtD
Fondaparinux sodium—F10—Metabolism of proteins—ADAMTS17—liver cancer	0.0032	0.0117	CbGpPWpGaD
Fondaparinux sodium—Angiopathy—Sorafenib—liver cancer	0.00318	0.00438	CcSEcCtD
Fondaparinux sodium—Immune system disorder—Sorafenib—liver cancer	0.00317	0.00437	CcSEcCtD
Fondaparinux sodium—Mediastinal disorder—Sorafenib—liver cancer	0.00316	0.00436	CcSEcCtD
Fondaparinux sodium—Arrhythmia—Sorafenib—liver cancer	0.00313	0.00432	CcSEcCtD
Fondaparinux sodium—Malnutrition—Sorafenib—liver cancer	0.00305	0.00421	CcSEcCtD
Fondaparinux sodium—Necrosis—Doxorubicin—liver cancer	0.00304	0.00419	CcSEcCtD
Fondaparinux sodium—Feeling hot—Doxorubicin—liver cancer	0.00304	0.00419	CcSEcCtD
Fondaparinux sodium—Abscess—Doxorubicin—liver cancer	0.00302	0.00416	CcSEcCtD
Fondaparinux sodium—F10—Complement and Coagulation Cascades—SERPINE1—liver cancer	0.00301	0.011	CbGpPWpGaD
Fondaparinux sodium—Dysgeusia—Sorafenib—liver cancer	0.00299	0.00412	CcSEcCtD
Fondaparinux sodium—Extravasation—Epirubicin—liver cancer	0.00296	0.00408	CcSEcCtD
Fondaparinux sodium—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00284	0.00391	CcSEcCtD
Fondaparinux sodium—Cellulitis—Epirubicin—liver cancer	0.00284	0.00391	CcSEcCtD
Fondaparinux sodium—Anaemia—Sorafenib—liver cancer	0.00282	0.00389	CcSEcCtD
Fondaparinux sodium—Hypocalcaemia—Epirubicin—liver cancer	0.00282	0.00389	CcSEcCtD
Fondaparinux sodium—Oliguria—Epirubicin—liver cancer	0.0028	0.00386	CcSEcCtD
Fondaparinux sodium—Angioedema—Sorafenib—liver cancer	0.00279	0.00384	CcSEcCtD
Fondaparinux sodium—Syncope—Sorafenib—liver cancer	0.00274	0.00377	CcSEcCtD
Fondaparinux sodium—Extravasation—Doxorubicin—liver cancer	0.00274	0.00377	CcSEcCtD
Fondaparinux sodium—Ulcer—Epirubicin—liver cancer	0.00273	0.00376	CcSEcCtD
Fondaparinux sodium—Creatinine increased—Epirubicin—liver cancer	0.00271	0.00374	CcSEcCtD
Fondaparinux sodium—Loss of consciousness—Sorafenib—liver cancer	0.00268	0.0037	CcSEcCtD
Fondaparinux sodium—Cough—Sorafenib—liver cancer	0.00266	0.00367	CcSEcCtD
Fondaparinux sodium—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.00263	0.00362	CcSEcCtD
Fondaparinux sodium—Cellulitis—Doxorubicin—liver cancer	0.00263	0.00362	CcSEcCtD
Fondaparinux sodium—Hypocalcaemia—Doxorubicin—liver cancer	0.00261	0.00359	CcSEcCtD
Fondaparinux sodium—Oliguria—Doxorubicin—liver cancer	0.00259	0.00357	CcSEcCtD
Fondaparinux sodium—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00258	0.00356	CcSEcCtD
Fondaparinux sodium—Hepatocellular injury—Epirubicin—liver cancer	0.00258	0.00356	CcSEcCtD
Fondaparinux sodium—Ventricular tachycardia—Epirubicin—liver cancer	0.00258	0.00356	CcSEcCtD
Fondaparinux sodium—Ulcer—Doxorubicin—liver cancer	0.00252	0.00348	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—SERPINA1—liver cancer	0.00251	0.00913	CbGpPWpGaD
Fondaparinux sodium—Creatinine increased—Doxorubicin—liver cancer	0.00251	0.00346	CcSEcCtD
Fondaparinux sodium—Anaphylactic shock—Sorafenib—liver cancer	0.00249	0.00343	CcSEcCtD
Fondaparinux sodium—Infection—Sorafenib—liver cancer	0.00247	0.00341	CcSEcCtD
Fondaparinux sodium—Shock—Sorafenib—liver cancer	0.00245	0.00338	CcSEcCtD
Fondaparinux sodium—Fluid retention—Epirubicin—liver cancer	0.00245	0.00338	CcSEcCtD
Fondaparinux sodium—Nervous system disorder—Sorafenib—liver cancer	0.00244	0.00337	CcSEcCtD
Fondaparinux sodium—Thrombocytopenia—Sorafenib—liver cancer	0.00244	0.00336	CcSEcCtD
Fondaparinux sodium—Blood urea increased—Epirubicin—liver cancer	0.00244	0.00336	CcSEcCtD
Fondaparinux sodium—F10—Metabolism of proteins—YIF1A—liver cancer	0.00243	0.00884	CbGpPWpGaD
Fondaparinux sodium—Skin disorder—Sorafenib—liver cancer	0.00242	0.00334	CcSEcCtD
Fondaparinux sodium—Hepatocellular injury—Doxorubicin—liver cancer	0.00239	0.00329	CcSEcCtD
Fondaparinux sodium—Ventricular tachycardia—Doxorubicin—liver cancer	0.00239	0.00329	CcSEcCtD
Fondaparinux sodium—Anorexia—Sorafenib—liver cancer	0.00237	0.00327	CcSEcCtD
Fondaparinux sodium—Fluid retention—Doxorubicin—liver cancer	0.00227	0.00312	CcSEcCtD
Fondaparinux sodium—Blood urea increased—Doxorubicin—liver cancer	0.00225	0.00311	CcSEcCtD
Fondaparinux sodium—Sepsis—Epirubicin—liver cancer	0.00224	0.00309	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Sorafenib—liver cancer	0.00222	0.00306	CcSEcCtD
Fondaparinux sodium—Dyspepsia—Sorafenib—liver cancer	0.00219	0.00302	CcSEcCtD
Fondaparinux sodium—Phlebitis—Epirubicin—liver cancer	0.00217	0.003	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Sorafenib—liver cancer	0.00217	0.00298	CcSEcCtD
Fondaparinux sodium—Gastrointestinal disorder—Sorafenib—liver cancer	0.00215	0.00296	CcSEcCtD
Fondaparinux sodium—Fatigue—Sorafenib—liver cancer	0.00215	0.00296	CcSEcCtD
Fondaparinux sodium—Hepatic function abnormal—Epirubicin—liver cancer	0.00214	0.00295	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—ANXA2—liver cancer	0.00214	0.00779	CbGpPWpGaD
Fondaparinux sodium—Pain—Sorafenib—liver cancer	0.00213	0.00294	CcSEcCtD
Fondaparinux sodium—Constipation—Sorafenib—liver cancer	0.00213	0.00294	CcSEcCtD
Fondaparinux sodium—Vascular purpura—Epirubicin—liver cancer	0.00209	0.00289	CcSEcCtD
Fondaparinux sodium—Sepsis—Doxorubicin—liver cancer	0.00207	0.00286	CcSEcCtD
Fondaparinux sodium—Cardiac failure congestive—Epirubicin—liver cancer	0.00207	0.00285	CcSEcCtD
Fondaparinux sodium—Gastrointestinal pain—Sorafenib—liver cancer	0.00204	0.00281	CcSEcCtD
Fondaparinux sodium—Renal failure acute—Epirubicin—liver cancer	0.00203	0.0028	CcSEcCtD
Fondaparinux sodium—Phlebitis—Doxorubicin—liver cancer	0.00201	0.00277	CcSEcCtD
Fondaparinux sodium—Hot flush—Epirubicin—liver cancer	0.002	0.00276	CcSEcCtD
Fondaparinux sodium—F10—Metabolism of proteins—EXOSC2—liver cancer	0.002	0.00728	CbGpPWpGaD
Fondaparinux sodium—Menopausal symptoms—Epirubicin—liver cancer	0.00198	0.00274	CcSEcCtD
Fondaparinux sodium—Hepatic function abnormal—Doxorubicin—liver cancer	0.00198	0.00273	CcSEcCtD
Fondaparinux sodium—Urticaria—Sorafenib—liver cancer	0.00198	0.00273	CcSEcCtD
Fondaparinux sodium—Abdominal pain—Sorafenib—liver cancer	0.00197	0.00271	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Sorafenib—liver cancer	0.00197	0.00271	CcSEcCtD
Fondaparinux sodium—Renal impairment—Epirubicin—liver cancer	0.00197	0.00271	CcSEcCtD
Fondaparinux sodium—Dermatitis bullous—Epirubicin—liver cancer	0.00196	0.0027	CcSEcCtD
Fondaparinux sodium—Purpura—Epirubicin—liver cancer	0.00194	0.00268	CcSEcCtD
Fondaparinux sodium—Vascular purpura—Doxorubicin—liver cancer	0.00194	0.00267	CcSEcCtD
Fondaparinux sodium—Cardiac failure—Epirubicin—liver cancer	0.00192	0.00265	CcSEcCtD
Fondaparinux sodium—Cerebrovascular accident—Epirubicin—liver cancer	0.00191	0.00263	CcSEcCtD
Fondaparinux sodium—Cardiac failure congestive—Doxorubicin—liver cancer	0.00191	0.00263	CcSEcCtD
Fondaparinux sodium—Renal failure acute—Doxorubicin—liver cancer	0.00188	0.00259	CcSEcCtD
Fondaparinux sodium—Pain in extremity—Epirubicin—liver cancer	0.00187	0.00258	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—IFNA1—liver cancer	0.00187	0.0068	CbGpPWpGaD
Fondaparinux sodium—Hot flush—Doxorubicin—liver cancer	0.00185	0.00255	CcSEcCtD
Fondaparinux sodium—Menopausal symptoms—Doxorubicin—liver cancer	0.00184	0.00253	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Sorafenib—liver cancer	0.00184	0.00253	CcSEcCtD
Fondaparinux sodium—Renal impairment—Doxorubicin—liver cancer	0.00182	0.00251	CcSEcCtD
Fondaparinux sodium—Dermatitis bullous—Doxorubicin—liver cancer	0.00181	0.0025	CcSEcCtD
Fondaparinux sodium—Purpura—Doxorubicin—liver cancer	0.0018	0.00248	CcSEcCtD
Fondaparinux sodium—Asthenia—Sorafenib—liver cancer	0.00179	0.00246	CcSEcCtD
Fondaparinux sodium—Cardiac arrest—Epirubicin—liver cancer	0.00178	0.00245	CcSEcCtD
Fondaparinux sodium—Cardiac failure—Doxorubicin—liver cancer	0.00178	0.00245	CcSEcCtD
Fondaparinux sodium—Cerebrovascular accident—Doxorubicin—liver cancer	0.00177	0.00244	CcSEcCtD
Fondaparinux sodium—Pruritus—Sorafenib—liver cancer	0.00176	0.00243	CcSEcCtD
Fondaparinux sodium—Blood creatinine increased—Epirubicin—liver cancer	0.00175	0.00242	CcSEcCtD
Fondaparinux sodium—Dehydration—Epirubicin—liver cancer	0.00174	0.0024	CcSEcCtD
Fondaparinux sodium—Pain in extremity—Doxorubicin—liver cancer	0.00173	0.00239	CcSEcCtD
Fondaparinux sodium—Hypokalaemia—Epirubicin—liver cancer	0.0017	0.00235	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Sorafenib—liver cancer	0.0017	0.00235	CcSEcCtD
Fondaparinux sodium—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00169	0.00232	CcSEcCtD
Fondaparinux sodium—Gastritis—Epirubicin—liver cancer	0.00166	0.00228	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—PRKCE—liver cancer	0.00165	0.00602	CbGpPWpGaD
Fondaparinux sodium—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00165	0.00228	CcSEcCtD
Fondaparinux sodium—Cardiac arrest—Doxorubicin—liver cancer	0.00165	0.00227	CcSEcCtD
Fondaparinux sodium—Dizziness—Sorafenib—liver cancer	0.00165	0.00227	CcSEcCtD
Fondaparinux sodium—Abdominal distension—Epirubicin—liver cancer	0.00163	0.00225	CcSEcCtD
Fondaparinux sodium—Blood creatinine increased—Doxorubicin—liver cancer	0.00162	0.00224	CcSEcCtD
Fondaparinux sodium—Dysphagia—Epirubicin—liver cancer	0.00162	0.00223	CcSEcCtD
Fondaparinux sodium—Dehydration—Doxorubicin—liver cancer	0.00161	0.00222	CcSEcCtD
Fondaparinux sodium—Vomiting—Sorafenib—liver cancer	0.00158	0.00218	CcSEcCtD
Fondaparinux sodium—Hypokalaemia—Doxorubicin—liver cancer	0.00158	0.00217	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—ABL1—liver cancer	0.00157	0.00573	CbGpPWpGaD
Fondaparinux sodium—Rash—Sorafenib—liver cancer	0.00157	0.00216	CcSEcCtD
Fondaparinux sodium—Dermatitis—Sorafenib—liver cancer	0.00157	0.00216	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—IGF2—liver cancer	0.00157	0.0057	CbGpPWpGaD
Fondaparinux sodium—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00156	0.00215	CcSEcCtD
Fondaparinux sodium—Headache—Sorafenib—liver cancer	0.00156	0.00215	CcSEcCtD
Fondaparinux sodium—Bronchitis—Epirubicin—liver cancer	0.00156	0.00215	CcSEcCtD
Fondaparinux sodium—Gastritis—Doxorubicin—liver cancer	0.00153	0.00211	CcSEcCtD
Fondaparinux sodium—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00153	0.00211	CcSEcCtD
Fondaparinux sodium—Abdominal distension—Doxorubicin—liver cancer	0.00151	0.00208	CcSEcCtD
Fondaparinux sodium—Dysphagia—Doxorubicin—liver cancer	0.0015	0.00206	CcSEcCtD
Fondaparinux sodium—Nausea—Sorafenib—liver cancer	0.00148	0.00204	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—HGF—liver cancer	0.00148	0.00538	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Hemostasis—CSF2—liver cancer	0.00146	0.00532	CbGpPWpGaD
Fondaparinux sodium—Infestation NOS—Epirubicin—liver cancer	0.00144	0.00199	CcSEcCtD
Fondaparinux sodium—Infestation—Epirubicin—liver cancer	0.00144	0.00199	CcSEcCtD
Fondaparinux sodium—Bronchitis—Doxorubicin—liver cancer	0.00144	0.00199	CcSEcCtD
Fondaparinux sodium—Renal failure—Epirubicin—liver cancer	0.00142	0.00196	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—SERPINA1—liver cancer	0.00142	0.00516	CbGpPWpGaD
Fondaparinux sodium—Urinary tract infection—Epirubicin—liver cancer	0.0014	0.00193	CcSEcCtD
Fondaparinux sodium—Haematuria—Epirubicin—liver cancer	0.00138	0.0019	CcSEcCtD
Fondaparinux sodium—Hepatobiliary disease—Epirubicin—liver cancer	0.00136	0.00188	CcSEcCtD
Fondaparinux sodium—Epistaxis—Epirubicin—liver cancer	0.00136	0.00188	CcSEcCtD
Fondaparinux sodium—Infestation NOS—Doxorubicin—liver cancer	0.00134	0.00184	CcSEcCtD
Fondaparinux sodium—Infestation—Doxorubicin—liver cancer	0.00134	0.00184	CcSEcCtD
Fondaparinux sodium—Renal failure—Doxorubicin—liver cancer	0.00131	0.00181	CcSEcCtD
Fondaparinux sodium—Haemoglobin—Epirubicin—liver cancer	0.0013	0.0018	CcSEcCtD
Fondaparinux sodium—Urinary tract infection—Doxorubicin—liver cancer	0.0013	0.00179	CcSEcCtD
Fondaparinux sodium—Haemorrhage—Epirubicin—liver cancer	0.0013	0.00179	CcSEcCtD
Fondaparinux sodium—Hypoaesthesia—Epirubicin—liver cancer	0.00129	0.00178	CcSEcCtD
Fondaparinux sodium—Oedema peripheral—Epirubicin—liver cancer	0.00128	0.00176	CcSEcCtD
Fondaparinux sodium—Haematuria—Doxorubicin—liver cancer	0.00127	0.00176	CcSEcCtD
Fondaparinux sodium—Hepatobiliary disease—Doxorubicin—liver cancer	0.00126	0.00174	CcSEcCtD
Fondaparinux sodium—Epistaxis—Doxorubicin—liver cancer	0.00126	0.00174	CcSEcCtD
Fondaparinux sodium—Haemoglobin—Doxorubicin—liver cancer	0.0012	0.00166	CcSEcCtD
Fondaparinux sodium—Flushing—Epirubicin—liver cancer	0.0012	0.00166	CcSEcCtD
Fondaparinux sodium—Haemorrhage—Doxorubicin—liver cancer	0.0012	0.00165	CcSEcCtD
Fondaparinux sodium—Hypoaesthesia—Doxorubicin—liver cancer	0.00119	0.00164	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—MAPK14—liver cancer	0.00118	0.00431	CbGpPWpGaD
Fondaparinux sodium—Oedema peripheral—Doxorubicin—liver cancer	0.00118	0.00163	CcSEcCtD
Fondaparinux sodium—Angiopathy—Epirubicin—liver cancer	0.00118	0.00162	CcSEcCtD
Fondaparinux sodium—Immune system disorder—Epirubicin—liver cancer	0.00117	0.00161	CcSEcCtD
Fondaparinux sodium—Mediastinal disorder—Epirubicin—liver cancer	0.00117	0.00161	CcSEcCtD
Fondaparinux sodium—Arrhythmia—Epirubicin—liver cancer	0.00116	0.0016	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—F2—liver cancer	0.00115	0.00418	CbGpPWpGaD
Fondaparinux sodium—Malnutrition—Epirubicin—liver cancer	0.00113	0.00155	CcSEcCtD
Fondaparinux sodium—F10—Metabolism of proteins—ATF3—liver cancer	0.00112	0.00409	CbGpPWpGaD
Fondaparinux sodium—Flushing—Doxorubicin—liver cancer	0.00111	0.00153	CcSEcCtD
Fondaparinux sodium—Flatulence—Epirubicin—liver cancer	0.00111	0.00153	CcSEcCtD
Fondaparinux sodium—Dysgeusia—Epirubicin—liver cancer	0.0011	0.00152	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—PIK3CG—liver cancer	0.0011	0.004	CbGpPWpGaD
Fondaparinux sodium—Back pain—Epirubicin—liver cancer	0.00109	0.0015	CcSEcCtD
Fondaparinux sodium—Angiopathy—Doxorubicin—liver cancer	0.00109	0.0015	CcSEcCtD
Fondaparinux sodium—Immune system disorder—Doxorubicin—liver cancer	0.00108	0.00149	CcSEcCtD
Fondaparinux sodium—Mediastinal disorder—Doxorubicin—liver cancer	0.00108	0.00149	CcSEcCtD
Fondaparinux sodium—F10—Post-translational protein modification—F2—liver cancer	0.00107	0.00391	CbGpPWpGaD
Fondaparinux sodium—Arrhythmia—Doxorubicin—liver cancer	0.00107	0.00148	CcSEcCtD
Fondaparinux sodium—Vision blurred—Epirubicin—liver cancer	0.00106	0.00147	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—IFNA1—liver cancer	0.00106	0.00384	CbGpPWpGaD
Fondaparinux sodium—Malnutrition—Doxorubicin—liver cancer	0.00104	0.00144	CcSEcCtD
Fondaparinux sodium—Anaemia—Epirubicin—liver cancer	0.00104	0.00144	CcSEcCtD
Fondaparinux sodium—Flatulence—Doxorubicin—liver cancer	0.00103	0.00142	CcSEcCtD
Fondaparinux sodium—Dysgeusia—Doxorubicin—liver cancer	0.00102	0.00141	CcSEcCtD
Fondaparinux sodium—Vertigo—Epirubicin—liver cancer	0.00101	0.0014	CcSEcCtD
Fondaparinux sodium—Syncope—Epirubicin—liver cancer	0.00101	0.00139	CcSEcCtD
Fondaparinux sodium—Back pain—Doxorubicin—liver cancer	0.00101	0.00139	CcSEcCtD
Fondaparinux sodium—Palpitations—Epirubicin—liver cancer	0.000997	0.00137	CcSEcCtD
Fondaparinux sodium—Loss of consciousness—Epirubicin—liver cancer	0.000991	0.00137	CcSEcCtD
Fondaparinux sodium—Cough—Epirubicin—liver cancer	0.000984	0.00136	CcSEcCtD
Fondaparinux sodium—Vision blurred—Doxorubicin—liver cancer	0.000983	0.00136	CcSEcCtD
Fondaparinux sodium—Convulsion—Epirubicin—liver cancer	0.000977	0.00135	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—PIK3CD—liver cancer	0.000965	0.00351	CbGpPWpGaD
Fondaparinux sodium—Anaemia—Doxorubicin—liver cancer	0.000965	0.00133	CcSEcCtD
Fondaparinux sodium—Chest pain—Epirubicin—liver cancer	0.00096	0.00132	CcSEcCtD
Fondaparinux sodium—Anxiety—Epirubicin—liver cancer	0.000957	0.00132	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—SERPINE1—liver cancer	0.000954	0.00348	CbGpPWpGaD
Fondaparinux sodium—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000954	0.00131	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—ALB—liver cancer	0.000952	0.00347	CbGpPWpGaD
Fondaparinux sodium—Vertigo—Doxorubicin—liver cancer	0.000938	0.00129	CcSEcCtD
Fondaparinux sodium—Syncope—Doxorubicin—liver cancer	0.000936	0.00129	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—PRKCE—liver cancer	0.000933	0.0034	CbGpPWpGaD
Fondaparinux sodium—Confusional state—Epirubicin—liver cancer	0.000928	0.00128	CcSEcCtD
Fondaparinux sodium—Palpitations—Doxorubicin—liver cancer	0.000922	0.00127	CcSEcCtD
Fondaparinux sodium—Anaphylactic shock—Epirubicin—liver cancer	0.00092	0.00127	CcSEcCtD
Fondaparinux sodium—Oedema—Epirubicin—liver cancer	0.00092	0.00127	CcSEcCtD
Fondaparinux sodium—Loss of consciousness—Doxorubicin—liver cancer	0.000917	0.00126	CcSEcCtD
Fondaparinux sodium—Infection—Epirubicin—liver cancer	0.000914	0.00126	CcSEcCtD
Fondaparinux sodium—Cough—Doxorubicin—liver cancer	0.000911	0.00126	CcSEcCtD
Fondaparinux sodium—Shock—Epirubicin—liver cancer	0.000906	0.00125	CcSEcCtD
Fondaparinux sodium—Convulsion—Doxorubicin—liver cancer	0.000904	0.00125	CcSEcCtD
Fondaparinux sodium—Nervous system disorder—Epirubicin—liver cancer	0.000903	0.00124	CcSEcCtD
Fondaparinux sodium—Thrombocytopenia—Epirubicin—liver cancer	0.000901	0.00124	CcSEcCtD
Fondaparinux sodium—Tachycardia—Epirubicin—liver cancer	0.000898	0.00124	CcSEcCtD
Fondaparinux sodium—Skin disorder—Epirubicin—liver cancer	0.000894	0.00123	CcSEcCtD
Fondaparinux sodium—Hyperhidrosis—Epirubicin—liver cancer	0.00089	0.00123	CcSEcCtD
Fondaparinux sodium—Chest pain—Doxorubicin—liver cancer	0.000888	0.00122	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—ABL1—liver cancer	0.000888	0.00324	CbGpPWpGaD
Fondaparinux sodium—Anxiety—Doxorubicin—liver cancer	0.000885	0.00122	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—IGF2—liver cancer	0.000884	0.00322	CbGpPWpGaD
Fondaparinux sodium—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000882	0.00122	CcSEcCtD
Fondaparinux sodium—Anorexia—Epirubicin—liver cancer	0.000877	0.00121	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—RAF1—liver cancer	0.000861	0.00314	CbGpPWpGaD
Fondaparinux sodium—Hypotension—Epirubicin—liver cancer	0.00086	0.00119	CcSEcCtD
Fondaparinux sodium—Confusional state—Doxorubicin—liver cancer	0.000859	0.00118	CcSEcCtD
Fondaparinux sodium—Oedema—Doxorubicin—liver cancer	0.000852	0.00117	CcSEcCtD
Fondaparinux sodium—Anaphylactic shock—Doxorubicin—liver cancer	0.000852	0.00117	CcSEcCtD
Fondaparinux sodium—Infection—Doxorubicin—liver cancer	0.000846	0.00117	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—PIK3CB—liver cancer	0.000841	0.00306	CbGpPWpGaD
Fondaparinux sodium—Shock—Doxorubicin—liver cancer	0.000838	0.00116	CcSEcCtD
Fondaparinux sodium—Nervous system disorder—Doxorubicin—liver cancer	0.000835	0.00115	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—HGF—liver cancer	0.000835	0.00304	CbGpPWpGaD
Fondaparinux sodium—Thrombocytopenia—Doxorubicin—liver cancer	0.000834	0.00115	CcSEcCtD
Fondaparinux sodium—Insomnia—Epirubicin—liver cancer	0.000833	0.00115	CcSEcCtD
Fondaparinux sodium—Tachycardia—Doxorubicin—liver cancer	0.000831	0.00115	CcSEcCtD
Fondaparinux sodium—Skin disorder—Doxorubicin—liver cancer	0.000827	0.00114	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Epirubicin—liver cancer	0.000827	0.00114	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—CSF2—liver cancer	0.000826	0.00301	CbGpPWpGaD
Fondaparinux sodium—Hyperhidrosis—Doxorubicin—liver cancer	0.000823	0.00114	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Epirubicin—liver cancer	0.000821	0.00113	CcSEcCtD
Fondaparinux sodium—Somnolence—Epirubicin—liver cancer	0.000818	0.00113	CcSEcCtD
Fondaparinux sodium—Anorexia—Doxorubicin—liver cancer	0.000812	0.00112	CcSEcCtD
Fondaparinux sodium—Dyspepsia—Epirubicin—liver cancer	0.00081	0.00112	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Epirubicin—liver cancer	0.0008	0.0011	CcSEcCtD
Fondaparinux sodium—Hypotension—Doxorubicin—liver cancer	0.000796	0.0011	CcSEcCtD
Fondaparinux sodium—Gastrointestinal disorder—Epirubicin—liver cancer	0.000795	0.0011	CcSEcCtD
Fondaparinux sodium—Fatigue—Epirubicin—liver cancer	0.000794	0.00109	CcSEcCtD
Fondaparinux sodium—Constipation—Epirubicin—liver cancer	0.000787	0.00109	CcSEcCtD
Fondaparinux sodium—Pain—Epirubicin—liver cancer	0.000787	0.00109	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—IL2—liver cancer	0.000772	0.00281	CbGpPWpGaD
Fondaparinux sodium—Insomnia—Doxorubicin—liver cancer	0.00077	0.00106	CcSEcCtD
Fondaparinux sodium—Paraesthesia—Doxorubicin—liver cancer	0.000765	0.00105	CcSEcCtD
Fondaparinux sodium—Dyspnoea—Doxorubicin—liver cancer	0.000759	0.00105	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Epirubicin—liver cancer	0.000759	0.00105	CcSEcCtD
Fondaparinux sodium—Somnolence—Doxorubicin—liver cancer	0.000757	0.00104	CcSEcCtD
Fondaparinux sodium—Gastrointestinal pain—Epirubicin—liver cancer	0.000753	0.00104	CcSEcCtD
Fondaparinux sodium—Dyspepsia—Doxorubicin—liver cancer	0.00075	0.00103	CcSEcCtD
Fondaparinux sodium—Decreased appetite—Doxorubicin—liver cancer	0.00074	0.00102	CcSEcCtD
Fondaparinux sodium—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000735	0.00101	CcSEcCtD
Fondaparinux sodium—Fatigue—Doxorubicin—liver cancer	0.000734	0.00101	CcSEcCtD
Fondaparinux sodium—Urticaria—Epirubicin—liver cancer	0.000731	0.00101	CcSEcCtD
Fondaparinux sodium—Pain—Doxorubicin—liver cancer	0.000728	0.001	CcSEcCtD
Fondaparinux sodium—Constipation—Doxorubicin—liver cancer	0.000728	0.001	CcSEcCtD
Fondaparinux sodium—Abdominal pain—Epirubicin—liver cancer	0.000728	0.001	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Epirubicin—liver cancer	0.000728	0.001	CcSEcCtD
Fondaparinux sodium—Feeling abnormal—Doxorubicin—liver cancer	0.000702	0.000968	CcSEcCtD
Fondaparinux sodium—Gastrointestinal pain—Doxorubicin—liver cancer	0.000696	0.00096	CcSEcCtD
Fondaparinux sodium—F10—Metabolism of proteins—IGF2—liver cancer	0.000696	0.00253	CbGpPWpGaD
Fondaparinux sodium—Hypersensitivity—Epirubicin—liver cancer	0.000678	0.000935	CcSEcCtD
Fondaparinux sodium—Urticaria—Doxorubicin—liver cancer	0.000677	0.000933	CcSEcCtD
Fondaparinux sodium—Abdominal pain—Doxorubicin—liver cancer	0.000673	0.000928	CcSEcCtD
Fondaparinux sodium—Body temperature increased—Doxorubicin—liver cancer	0.000673	0.000928	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—MAPK14—liver cancer	0.000669	0.00244	CbGpPWpGaD
Fondaparinux sodium—Asthenia—Epirubicin—liver cancer	0.00066	0.00091	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—VEGFA—liver cancer	0.000656	0.00239	CbGpPWpGaD
Fondaparinux sodium—Pruritus—Epirubicin—liver cancer	0.000651	0.000898	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—F2—liver cancer	0.000648	0.00236	CbGpPWpGaD
Fondaparinux sodium—Diarrhoea—Epirubicin—liver cancer	0.00063	0.000868	CcSEcCtD
Fondaparinux sodium—Hypersensitivity—Doxorubicin—liver cancer	0.000627	0.000865	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—PIK3CG—liver cancer	0.00062	0.00226	CbGpPWpGaD
Fondaparinux sodium—Asthenia—Doxorubicin—liver cancer	0.000611	0.000842	CcSEcCtD
Fondaparinux sodium—Dizziness—Epirubicin—liver cancer	0.000609	0.000839	CcSEcCtD
Fondaparinux sodium—Pruritus—Doxorubicin—liver cancer	0.000603	0.000831	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—TGFB1—liver cancer	0.000602	0.00219	CbGpPWpGaD
Fondaparinux sodium—Vomiting—Epirubicin—liver cancer	0.000585	0.000807	CcSEcCtD
Fondaparinux sodium—Diarrhoea—Doxorubicin—liver cancer	0.000583	0.000803	CcSEcCtD
Fondaparinux sodium—Rash—Epirubicin—liver cancer	0.00058	0.0008	CcSEcCtD
Fondaparinux sodium—Dermatitis—Epirubicin—liver cancer	0.00058	0.000799	CcSEcCtD
Fondaparinux sodium—Headache—Epirubicin—liver cancer	0.000577	0.000795	CcSEcCtD
Fondaparinux sodium—Dizziness—Doxorubicin—liver cancer	0.000563	0.000776	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—KRAS—liver cancer	0.000558	0.00203	CbGpPWpGaD
Fondaparinux sodium—Nausea—Epirubicin—liver cancer	0.000547	0.000754	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—PIK3CD—liver cancer	0.000545	0.00199	CbGpPWpGaD
Fondaparinux sodium—Vomiting—Doxorubicin—liver cancer	0.000542	0.000747	CcSEcCtD
Fondaparinux sodium—F10—Hemostasis—SERPINE1—liver cancer	0.000539	0.00196	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—ALB—liver cancer	0.000538	0.00196	CbGpPWpGaD
Fondaparinux sodium—Rash—Doxorubicin—liver cancer	0.000537	0.00074	CcSEcCtD
Fondaparinux sodium—Dermatitis—Doxorubicin—liver cancer	0.000537	0.00074	CcSEcCtD
Fondaparinux sodium—Headache—Doxorubicin—liver cancer	0.000534	0.000736	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—PIK3CA—liver cancer	0.000513	0.00187	CbGpPWpGaD
Fondaparinux sodium—F10—Metabolism of proteins—F2—liver cancer	0.00051	0.00186	CbGpPWpGaD
Fondaparinux sodium—Nausea—Doxorubicin—liver cancer	0.000506	0.000697	CcSEcCtD
Fondaparinux sodium—SERPINC1—Hemostasis—TP53—liver cancer	0.000496	0.00181	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—RAF1—liver cancer	0.000487	0.00177	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—PIK3CB—liver cancer	0.000475	0.00173	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Hemostasis—HRAS—liver cancer	0.000474	0.00173	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—IL2—liver cancer	0.000436	0.00159	CbGpPWpGaD
Fondaparinux sodium—F10—Metabolism of proteins—MMP2—liver cancer	0.000432	0.00157	CbGpPWpGaD
Fondaparinux sodium—SERPINC1—Hemostasis—AKT1—liver cancer	0.000419	0.00153	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—VEGFA—liver cancer	0.000371	0.00135	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—TGFB1—liver cancer	0.00034	0.00124	CbGpPWpGaD
Fondaparinux sodium—F10—Metabolism of proteins—CTNNB1—liver cancer	0.000331	0.00121	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—KRAS—liver cancer	0.000315	0.00115	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—PIK3CA—liver cancer	0.00029	0.00105	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—TP53—liver cancer	0.00028	0.00102	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—HRAS—liver cancer	0.000268	0.000976	CbGpPWpGaD
Fondaparinux sodium—F10—Hemostasis—AKT1—liver cancer	0.000237	0.000862	CbGpPWpGaD
